A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain
Latest Information Update: 04 Apr 2024
At a glance
- Drugs Eliapixant (Primary) ; Pregabalin
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms PUCCINI
- Sponsors Bayer
- 01 Apr 2024 Primary endpoint (Change from baseline in weekly mean 24-hour average pain intensity score at week 8) has not been met as per results published in the Pain
- 01 Apr 2024 Results published in the Pain
- 20 Mar 2022 This trial has been completed in Czechia , according to European Clinical Trials Database record.